

Product Update:

atazanavir/cobicistat 300mg/150mg film-coated tablets (Evotaz[®])
SMC No. (1098/15)

Bristol-Myers Squibb Pharmaceuticals Ltd

9 October 2015

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

atazanavir/cobicistat (Evotaz[®]) is accepted for use within NHS Scotland.

Indication under review: in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.

Pharmacokinetic studies have demonstrated that atazanavir plus cobicistat is bioequivalent (in terms of atazanavir exposure) to ritonavir-boosted atazanavir.

For patients in whom atazanavir is an appropriate treatment, atazanavir/cobicistat (Evotaz[®]) provides a combination product at a small cost premium compared to ritonavir-boosted atazanavir.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 04 September 2015.

Chairman
Scottish Medicines Consortium